GREER® Laboratories, Inc. Completes Deal with Ares Life Sciences
News May 01, 2013
“We are pleased that this transaction has been finalized, and we renew our commitment to allergy immunotherapy, our customers and their patients, ensuring that we will continue to deliver quality allergy immunotherapy products, services and customer support,” shares John G. Roby, GREER President and CEO.
GREER’s clinical development programs are focused on the company’s investigational sublingual allergy immunotherapy liquid (SAIL™). The company recently completed a successful Phase III study evaluating the efficacy and safety of GREER® SAIL™ as a treatment for adults with short ragweed allergies. Sublingual allergy immunotherapy (SLIT) is a method of allergy immunotherapy that delivers the same liquid allergenic extract approved for subcutaneous injections, but it is administered under the tongue. SLIT has been widely accepted as a safe, effective treatment for allergic rhinitis in Europe for years.1 However, SLIT is currently investigational in the United States.
Gilead Company Wins FDA Approval for CAR T Cancer Therapy for Treatment of Adult LymphomaNews
Kite’s Yescarta™ (axicabtagene ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.READ MORE
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
Mechanism Behind Inflammatory Response to Cytoplasmic DNA IdentifiedNews
A team led by LMU‘s Veit Hornung has elucidated the mechanism by which human cells induce inflammation upon detection of cytoplasmic DNA. Notably, the signal network involved differs from that used in the same context in mice.READ MORE